Lagmitaf is a fixed-dose combination antiretroviral medicine used to treat Human Immunodeficiency Virus type 1 (HIV-1) infection. It contains three active ingredients: bictegravir, emtricitabine, and tenofovir alafenamide. This once-daily tablet is designed to simplify HIV treatment by combining three powerful agents into a single pill, improving adherence and maintaining viral suppression. It is especially suited for individuals who are newly diagnosed or those who are already virologically suppressed and want a convenient treatment option.

Mechanism of Action:
Lagmitaf works by attacking the HIV virus at different stages of its life cycle, using a multi-targeted approach:

• Bictegravir is an integrase strand transfer inhibitor. It prevents the HIV virus from integrating its genetic material into the DNA of human immune cells. Without this step, the virus cannot replicate effectively.

• Emtricitabine is a nucleoside reverse transcriptase inhibitor. It mimics a natural building block of DNA and gets incorporated into the viral DNA chain, causing it to terminate early and preventing the virus from multiplying.

• Tenofovir alafenamide is a prodrug of tenofovir. Once inside liver and immune cells, it becomes active and inhibits the reverse transcriptase enzyme, further blocking viral replication.

  Uses:
  Lagmitaf is indicated for:

  • The treatment of HIV-1 infection in adults and adolescents weighing at least thirty-five kilograms.

  • It is suitable for people who are new to HIV treatment or those who are already virologically suppressed on a stable regimen and wish to switch to a more convenient therapy.

    Adverse Effects:
    Lagmitaf is generally well tolerated, but some people may experience side effects. Commonly reported ones include:

    • Headache

    • Diarrhea

    • Nausea

    • Fatigue

    • Trouble sleeping